scientific article; zbMATH DE number 5224906
From MaRDI portal
Publication:5434036
zbMATH Open1144.62097MaRDI QIDQ5434036FDOQ5434036
Authors: Yuan Ji, Yisheng Li, Guosheng Yin
Publication date: 9 January 2008
Title of this publication is not available (Why is that?)
Recommendations
- Bayesian Dose-Finding in Phase I/II Clinical Trials Using Toxicity and Efficacy Odds Ratios
- Phase I (or Phase II) Dose-Ranging Clinical Trials: Proposal of a Two-Stage Bayesian Design
- A Bayesian Approach to the Design of Phase II Clinical Trials
- Publication:3484242
- Bayesian designs for phase I--II clinical trials
- Bayesian design for clinical trials with a constraint on the total available dose
- Bayesian optimal designs for phase I clinical trials
Bayesian inference (62F15) Applications of statistics to biology and medical sciences; meta analysis (62P10) Monte Carlo methods (65C05) Numerical analysis or methods applied to Markov chains (65C40) Optimal stopping in statistics (62L15)
Cited In (15)
- Bayesian models and decision algorithms for complex early phase clinical trials
- Bayesian dose finding for combined drugs with discrete and continuous doses
- The treatment versus experimentation dilemma in dose finding studies
- Random-effects meta-analysis of phase I dose-finding studies using stochastic process priors
- Bayesian dose regimen assessment in early phase oncology incorporating pharmacokinetics and pharmacodynamics
- Dose Finding – A Challenge in Statistics
- Stochastic approximation with virtual observations for dose-finding on discrete levels
- DICE: A Bayesian model for early dose finding in phase I trials with multiple treatment courses
- Bayesian Model Averaging Continual Reassessment Method in Phase I Clinical Trials
- A Strategy for Dose-Finding and Safety Monitoring Based on Efficacy and Adverse Outcomes in Phase I/II Clinical Trials
- Phase I (or Phase II) Dose-Ranging Clinical Trials: Proposal of a Two-Stage Bayesian Design
- Adaptive clinical trial designs for phase I cancer studies
- Bayesian hierarchical random-effects meta-analysis and design of phase I clinical trials
- An application of reinforced urn processes to determining maximum tolerated dose
- Bayesian decision procedures based on logistic regression models for dose-finding studies
This page was built for publication:
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q5434036)